Serving the Society Since 1986
Advanced Search
Volume 23 Issue 2
April 2008
    Citation: Ina Schulte, E-juan ZHANG, Zhong-ji MENG, Rong-juan PEI, Mengji LU, Michael Roggendorf. Recent Advances in Research on Hepadnaviral Infection in the Woodchuck Model* .VIROLOGICA SINICA, 2008, 23(2) : 107-115.  http://dx.doi.org/10.1007/s12250-008-2941-z
    shu

    Recent Advances in Research on Hepadnaviral Infection in the Woodchuck Model*

    • 1.

      Institute of Virology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany

    • 2.

      Department of Microbiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    • 3.

      State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Chinas

    • Corresponding author: Michael Roggendorf, Michael.roggendorf@uni-due.de
    • Received Date: 22 December 2007
      Accepted Date: 24 January 2008
      Available online: 01 April 2008

      Fund Project: Deutsche Forschungsgemeinschaft Lu 669/5-1Deutsche Forschungsgemeinschaft Lu669/2-1Deutsche Forschungsgemeinschaft GRK1045/1

    • The woodchuck model is an excellent animal model to study hepadnaviral infection. The new progresses in this model made possible to examine the T-cell mediated immune responses in acute and chronic hepadnaviral infection. Recently, a new assay for cytotoxic T-cells based on detection of CD107 was established for the woodchuck model. In addition, new immunotherapeutic approaches based on combination of potent antiviral treatment and DNA-protein vaccines were proven to be useful for treatment of chronic hepatitis B.
    • 加载中

      1. Barber D L, Wherry E J, Masopust D, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439: 682-687.
          doi: 10.1038/nature04444

      2. Bertoletti A, Ferrari C, Fiaccadori F, et al. 1991. HLA class Ⅰ-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA, 88: 10445-10449.
          doi: 10.1073/pnas.88.23.10445

      3. Bertoletti A, Chisari F V, Penna A, et al. 1993. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol, 67: 2376-2380.

      4. Betts M R, Brenchley J M, Price D A, et al. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods, 281: 65-78.
          doi: 10.1016/S0022-1759(03)00265-5

      5. Boni C, Fisicaro P, Valdatta C, et al. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol, 81: 4215-4225.
          doi: 10.1128/JVI.02844-06

      6. Chisari F V, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. Annu Rev Immunol, 13: 29-60.
          doi: 10.1146/annurev.iy.13.040195.000333

      7. Colonno R J, Genovesi E V, Medina I, et al. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis, 184 (10): 1236-1245.
          doi: 10.1086/jid.2001.184.issue-10

      8. Cote P J, Gerin J. 1995. In vitro activation of woodchuck lymphocytes mesured by radiopurine incorporation and interluekin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection. Hepatology, 22: 687-699.

      9. Couillin I, Pol S, Mancini M F, et al. 1999. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis, 180: 15-26.
          doi: 10.1086/jid.1999.180.issue-1

      10. Day C L, Kaufmann D E, Kiepiela P, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443: 350-354.
          doi: 10.1038/nature05115

      11. Frank I, Budde C, Fiedler M, et al. 2007. Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol, 81: 7156-7163.
          doi: 10.1128/JVI.02711-06

      12. Freeman G J, Wherry E J, Ahmed R, et al. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 203:2223-2227.
          doi: 10.1084/jem.20061800

      13. Guidotti L G, Rochford R, Chung J, et al. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science, 284: 825-829.
          doi: 10.1126/science.284.5415.825

      14. Hervas-Stubbs S, Lasarte J J, Sarobe P, et al. 1997. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol, 27: 726-737.
          doi: 10.1016/S0168-8278(97)80090-6

      15. Hervas-Stubbs S, Lasarte J J, Sarobe P, et al. 2001. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronicallyinfected animals treated with lamivudine. J Hepatol, 35: 105-111.
          doi: 10.1016/S0168-8278(01)00063-0

      16. Horiike N, Fazle Akbar S M, Michitaka K, et al. 2003. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol, 32: 156-161.

      17. Hoofnagle J, Peters M, Mullen K D, et al. 1988. Randomized controlled trial of recombinant human alphainterferon in patients with chronic hepatitis B. Gastroenterology 95: 1318-1325.
          doi: 10.1016/0016-5085(88)90367-8

      18. Janssen H L, M van Zonneveld, Senturk H, et al. 2005. Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 365: 123-129.

      19. Jung M C, Gruner N, Zachoval R, et al. 2002. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies : induction of a vaccine-specific CD4+ T-cell proliferation response in chronic hepatitis B carriers. Vaccine, 20: 3598-3612.
          doi: 10.1016/S0264-410X(02)00309-2

      20. Kreuzfelder E, Menne S, Ferencik S， et al. 1996. Assessment of peripheral blood mononuclear cell proferation by 2 [3H] adenine uptake in the woodchuck model. Clin Immunol Immunpathol, 78: 223-227.
          doi: 10.1006/clin.1996.0033

      21. Lau G K, Piratvisuth T, Luo K X, et al. 2005. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352: 2682-2695.

      22. Locarnini S, Mason W S. 2006. Cellular and virological mechanisms of HBV drug resistance. J Hepatol, 44: 422-431.
          doi: 10.1016/j.jhep.2005.11.036

      23. Lu M, He L F, Xu Y, et al. 2008. Evaluation of combination therapies of chronic HBV infection with lamivudine and DNA-vaccines or antigen-antibody complexes in the woodchuck model. J Virol, in press.

      24. Lu M, Roggendorf M. 2001. Evaluation of New Approaches to Prophylactic and Therapeutic Vaccinations against Hepatitis B Viruses in the Woodchuck Model. Intervirology, 44: 124-131.
          doi: 10.1159/000050039

      25. Lu M, Klaes R, Menne S, et al. 2003. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol, 39: 405-413
          doi: 10.1016/S0168-8278(03)00241-1

      26. Lu M, Menne S, Yang D, et al. 2007. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin Investig Drugs 16: 787-801.
          doi: 10.1517/13543784.16.6.787

      27. Maini M K, Boni C, Lee C K, et al. 2000. The role of virus-specific CD8 (+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med, 191: 1269-1280.
          doi: 10.1084/jem.191.8.1269

      28. Maini M K, Boni C, Ogg G S, et al. 1999. Direct ex vivo analysis of hepatitis B virusspecific CD8+ T cells associated with the control of infection. Gastroenterology, 117: 1386-1396.
          doi: 10.1016/S0016-5085(99)70289-1

      29. Maschke J, Menne S, Jacob J R, et al. 2001. Thymidine utilization abnormality in proliferating lymphocytes and hepatocytes of the woodchuck. Vet Immunol Immunopath, 6403: 1-18.

      30. Menne S, Roneker C A, Korba B E, et al. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol, 76: 5305-5314.
          doi: 10.1128/JVI.76.11.5305-5314.2002

      31. Menne S, Maschke J, Tolle T K, et al. 1997. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol, 71: 65-74.

      32. Missale G, Redeker A, Person J, et al. 1993. HLA-A31-and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med, 177: 751-762.
          doi: 10.1084/jem.177.3.751

      33. Nayersina R, Fowler P, Guilhot S, et al. 1993. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol, 150: 4659-4671.

      34. Pol S, Nalpas B, Driss F, et al. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol, 34: 917-921.
          doi: 10.1016/S0168-8278(01)00028-9

      35. Pol S, Driss F, Michel M L, et al. 1994. Specific vaccine therapy in chronic hepatitis B infection. Lancet, 344: 342.

      36. Ponzetto A, Cote P J, Ford E C, et al. 1984. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus. J Virol, 52: 70-76.

      37. Raney A K, Hamatake R K, Hong Z. 2003. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs, 12: 1281-1295.
          doi: 10.1517/13543784.12.8.1281

      38. Rehermann B, Fowler P, Sidney J, et al. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med, 181: 1047-1058.
          doi: 10.1084/jem.181.3.1047

      39. Roggendorf M, Lu M. 2005. Woodchuck hepatitis virus. In: Viral Hepatitis (Thomas T H, Zuckermann A, Lemon S. ed. ), 3rd edition, Oxford: Blackwell Publishing Ltd. p210-224

      40. Roggendorf M, Lu M. 2006. Therapeutic vaccination in chronic hepadnavirus infection. In: New concepts of antiviral therapy (Dogner E, Holzenburg A. ed. ), Part 1. New York: Springer Berlin Heidelberg. p3-20

      41. Rubio V, Stuge T B, Singh N, et al. 2003. Ex vivo identification, isolation and analysis of tumorcytolytic T cells. Nat Med, 9: 1377-1382.
          doi: 10.1038/nm942

      42. Summers J, Smolec J M, Snyder R. 1978. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA, 75: 4533-4537.
          doi: 10.1073/pnas.75.9.4533

      43. Tang T J, Kwekkeboom J, Mancham S, et al. 2005. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol, 43: 45-52.
          doi: 10.1016/j.jhep.2005.01.038

      44. Thimme R, Chang K M, Pemberton J, et al. 2001. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLAB51. J Virol, 75: 3984-3987.
          doi: 10.1128/JVI.75.8.3984-3987.2001

      45. Thimme R, Wieland S, Steiger C, et al. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 77: 68-76.
          doi: 10.1128/JVI.77.1.68-76.2003

      46. Thimme R, Wieland S, Steiger C, et al. 2003. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 77: 68-76.
          doi: 10.1128/JVI.77.1.68-76.2003

      47. Webster G J, Reignat S, Maini M K, et al. 2000. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology, 32: 1117-1124.
          doi: 10.1053/jhep.2000.19324

      48. Wen Y M, Wu X H, Hu D C, et al. 1995. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet, 345: 1575-1576.

      49. Wong D C, Shih J W K, Purcell R H, et al. 1982. Natural and experimental infection of woodchucks with woodchuck hepatitis virus, a measured by new, specific assays for woodchuck surface antigen and antibody. J Clin Microbiol, 15: 484-490.

      50. Xu D Z, Huang K L, Zhao K, et al. 2005. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23: 2658-2664.
          doi: 10.1016/j.vaccine.2004.10.040

      51. Yalcin K, Acar M, Degertekin H. 2003. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection, 31: 221-225

      52. Yao X, Zheng B, Zhou J, et al. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25: 1771-1779.
          doi: 10.1016/j.vaccine.2006.11.019

      53. Zelinskyy G, Robertson S J, Schimmer S, et al. 2005. CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retro virus infection. J Virol, 79: 10619-10626.
          doi: 10.1128/JVI.79.16.10619-10626.2005

      54. Zhou J H, Ferencik S, Rebmann V, et al. 2003. Molecular genetic and biochemical analysis of woodchuck (Marmota monax) MHC class Ⅰ polymorphism. Tissue Antigens, 61: 240-248.
          doi: 10.1034/j.1399-0039.2003.00036.x

    • 加载中

    Figures(2)

    PDF

    Article Metrics

    Article views(3916) PDF downloads(21) Cited by()

    Related
    Proportional views

      Recent Advances in Research on Hepadnaviral Infection in the Woodchuck Model*

        Corresponding author: Michael Roggendorf, Michael.roggendorf@uni-due.de
      • 1. Institute of Virology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany
      • 2. Department of Microbiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
      • 3. State Key Lab of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, Chinas
      • Received Date: 22 December 2007
      • Accepted Date: 24 January 2008
      Fund Project:  Deutsche Forschungsgemeinschaft Lu 669/5-1Deutsche Forschungsgemeinschaft Lu669/2-1Deutsche Forschungsgemeinschaft GRK1045/1

      Abstract: The woodchuck model is an excellent animal model to study hepadnaviral infection. The new progresses in this model made possible to examine the T-cell mediated immune responses in acute and chronic hepadnaviral infection. Recently, a new assay for cytotoxic T-cells based on detection of CD107 was established for the woodchuck model. In addition, new immunotherapeutic approaches based on combination of potent antiviral treatment and DNA-protein vaccines were proven to be useful for treatment of chronic hepatitis B.

        HTML